TAK Latest Headlines

Takeda spotlights ORZEYFUL approvals and raises FY2026 forecast as reported operating profit jumps

Market Chameleon (Fri, 30-Oct 11:53 AM)

Takeda Pharmaceutical Non-GAAP EPS of ¥308.00, revenue of ¥2407B; upgrades FY 2026 outlook

at seekingalpha.com (Thu, 29-Oct 2:40 AM)

Takeda’s Mobocertinib Trial Update: What Lung Cancer Data Mean for TAK Investors

at www.tipranks.com (Wed, 28-Oct 12:30 PM)

Takeda Pharmaceutical Q2 Earnings Preview

at seekingalpha.com (Wed, 28-Oct 11:02 AM)

Takeda’s ORZEYFUL debuts in Japan and China after approvals within a month, putting a first-in-class orexin agonist into clinicians’ hands

Market Chameleon (Thu, 15-Oct 7:38 AM)

Takeda’s FDA Approval for ORZEYFUL Sets a New Standard in Narcolepsy Type 1 Care

Market Chameleon (Thu, 6-Aug 9:13 AM)